It wasnt just a shot
Your metabolic rate also adjusts during GLP-1 therapyyour body burns calories more efficiently because the medication reduces overall calorie intake and improves insulin sensitivity
Based on the mechanism of each component, the patients most likely to benefit from exploring KLOW with their physician are those who: Are actively on a GLP-1 receptor agonist (semaglutide, tirzepatide, retatrutide) and losing weight at a rate of 12+ lb/week Are experiencing visible skin laxity, facial volume loss, or skin texture changes as weight declines Have significant GI side effects (nausea, diarrhoea, mucosal discomfort) during dose escalation Carry known markers of systemic inflammation elevated hsCRP, elevated fasting insulin, or other metabolic biomarkers that have been flagged in prior lab work Are in their 40s or older, where baseline collagen decline makes the gap between demand and capacity most acute Have a history of inflammatory bowel conditions, slow wound healing, or joint/soft tissue injuries that have not fully resolved KLOW is less likely to be the primary tool for patients who are early in GLP-1 therapy, losing weight slowly, have no skin or GI symptoms, and carry no background inflammatory burden
It belongs to a class of drugs known as serotonin 5-HT3 receptor antagonists
Garshick notes that robust scientific evidence for certain supplements is still lacking, though anecdotally many patients do very well
Thus, patients with renal impairment may experience delayed elimination of GLP-1 metabolites
